Tomas Berl, Lawrence G Hunsicker, Julia B Lewis, Marc A Pfeffer, Jerome G Porush, Jean-Lucien Rouleau, Paul L Drury, Enric Esmatjes, Donald Hricik, Marc Pohl, Itamar Raz, Philippe Vanhille, Thomas B Wiegmann, Bernard M Wolfe, Francesco Locatelli, Samuel Z Goldhaber, Edmund J Lewis
Elevated arterial pressure enhances the risk for cardiovascular (CV) events in patients with diabetic nephropathy. The optimal BP and the component of the elevated BP that affect the risk have not been defined. A post hoc analysis was performed to assess the impact of achieved systolic, diastolic, and pulse pressures on CV outcomes in 1590 adults who had overt diabetic nephropathy and were enrolled in the Irbesartan Diabetic Nephropathy Trial (IDNT) and had a baseline serum creatinine above the normal range, up to 266 micromol/L (3...
July 2005: Journal of the American Society of Nephrology: JASN